A New Vaccine Was Designed by AI and Safey Tested on Humans

on PinterestA new vaccine designed by AI is the first to be tested on humans and may protect against a wide range of coronaviruses related to SARS and COVID-19.

on PinterestA new vaccine designed by AI is the first to be tested on humans and may protect against a wide range of coronaviruses related to SARS and COVID-19. miodrag ignjatovic/GettyImages

• Researchers have tested a vaccine designed to protect against a range of coronaviruses.
• This new vaccine was the first designed by AI to be tested on humans.
• The pEVAC-PS vaccine could enable protection against future mutations.
• The use of AI also enables the development of new vaccines much faster.
• However, more research is needed to determine whether it works in a more diverse population.

According to an article found in the June 2026 issue of the Journal of Infection, researchers have safely tested a new vaccine designed to protect against a wide range of coronaviruses related to SARS and COVID-19.

As a press release from the this trial is the first time that a vaccine whose active component was designed entirely by computer simulations has been tested in humans.

This vaccine, developed by a team of scientists from the the and DIOSynVax Ltd., is called pEVAC-PS.

The technology uses a “super-antigen” designed by artificial intelligence (AI) to create protection against a wide range of viruses, even when mutations occur.

Current methods for developing vaccines lack this ability, making frequent reformulations necessary to keep up with ever-changing viruses.

While the vaccine was found to be safe and without significant side effects, the authors say a larger trial is needed to determine whether it can provide strong protection in a more diverse population.

AI-designed vaccine tested on humans for the first time

In the study, it was given to healthy volunteers in the U.K. between December 2021 and September 2023.

The goal was to create a vaccine that could defend not only against current COVID-19 variants but also against future coronavirus threats that might potentially jump from animals to humans.

The authors say that the vaccine uses a needle-free DNA delivery system, making it easier to administer and store, especially in places with limited medical resources.

This phase I clinical trial involved 39 healthy adults between the ages of 18 and 50 who had already received 2 or 3 doses of COVID-19 vaccines but had not recently contracted the virus.

Participants were divided into four groups, each receiving different doses of the pEVAC-PS vaccine: 0.2 milligrams (mg), 0.4 mg, 0.8 mg, and 1.2 mg.

The vaccine was administered twice: the first dose on day 0 and the second on day 28.

Unlike traditional vaccines that use needles, pEVAC-PS was delivered intradermally (just under the skin) using a device called the PharmaJet Tropis, which delivers the vaccine without needles.

This needle-free method reduces the need for specialized medical equipment and lowers the risk of needle-related injuries or infections.

Volunteers were then carefully monitored for side effects and immune responses. They recorded any local reactions like redness or pain at the injection site, as well as systemic symptoms such as fever or fatigue, for seven days after each vaccination.

Blood samples were collected at several points before and after vaccination to measure immune responses, including antibodies that

Learn more about hair transplant at Rubenhair clinic.